



Synthesis of a staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety

Samir Messaoudi, Fabrice Anizon, Bruno Pfeiffer, Roy Golsteyn, Michelle Prudhomme

► To cite this version:

Samir Messaoudi, Fabrice Anizon, Bruno Pfeiffer, Roy Golsteyn, Michelle Prudhomme. Synthesis of a staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety. *Tetrahedron Letters*, Elsevier, 2004, 45, pp.4643-4647. <10.1016/j.tetlet.2004.04.102>. <hal-00136311>

HAL Id: hal-00136311

<https://hal.archives-ouvertes.fr/hal-00136311>

Submitted on 13 Mar 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Synthesis of a staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety

Samir Messaoudi,^a Fabrice Anizon,^a Bruno Pfeiffer,^b Roy Golsteyn^b
and Michelle Prudhomme^{a,*}

^aUniversité Blaise Pascal, Synthèse et Etude de Systèmes à Intérêt Biologique, UMR 6504 du CNRS, 63177 Aubière, France

^bInstitut de Recherches Servier, Division Recherche Cancérologie, 125 Chemin de ronde, 78290 Croissy sur Seine, France

Abstract—The synthesis of a new staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety is described. This synthesis could be achieved by coupling a sugar moiety previously tosylated in 2' position to the azaindolocarbazole aglycone. Nucleophilic substitution on the carbon bearing the tosyl group yielded to the key cyclization leading to a compound in which the carbohydrate part is linked to both indole and azaindole nitrogens.

1. Introduction

Staurosporine, a microbial metabolite isolated from cultures of *Streptomyces staurosporeus*, has been extensively studied as a potent and nonselective kinase inhibitor.^{1–3} Several academic and industrial groups have synthesized a large number of staurosporine analogues to obtain compounds exhibiting more selectivity toward the various kinases.⁴ In the search for new staurosporine analogues, we have previously synthesized rebeccamycin derivatives in which the carbohydrate moiety is linked to both indole nitrogens (Fig. 1).^{5,6} Rebeccamycin is an antitumor antibiotic produced from cultures of *Saccharothrix aerocolonigenes*. Rebeccamycin possesses an indolocarbazole framework onto which is attached via a β -*N*-glycosidic bond a 4-*O*-methoxyglucose. Its antitumor activity is linked to its capacity to inhibit topoisomerase I by forming a ternary DNA-topoisomerase I-drug complex that prevents the religation of the DNA strand cleaved by the enzyme.^{7,8} Contrary to rebeccamycin, staurosporine has no effect on topoisomerase I. Our staurosporine analogues pre-

viously obtained by semi-synthesis from rebeccamycin seem to have multiple targets and in contrast with rebeccamycin, they exhibit high selectivity toward the different tumor cell lines tested.

Azaindoles, as bioesters for indoles, present considerable biological importance. We have recently synthesized rebeccamycin analogues in which one or both indole moieties have been replaced by a 7-azaindole unit (Fig. 1).^{9,10} The newly introduced nitrogen atom(s) could modify the interactions with the target(s) enzyme(s).

In this Letter, we report the synthesis of a 7-aza-staurosporine analogue **1** bearing a methyl group on the imide nitrogen (Fig. 1).

2. Results and discussion

The previously achieved semi-synthesis of a staurosporine analogue in three steps from rebeccamycin is outlined in Scheme 1.⁵ Tosylation at 2' position on the sugar part was carried out before reaction using sodium azide, which led to two compounds, the major product of the reaction was the bridged compound obtained via deprotonation of the indole nitrogen followed by nucleophilic substitution at C2'. The minor product, 3'-azide, was formed via 2'-3'-epoxide. The last step was the removal of the chlorine atoms.

Keywords: Staurosporine; Rebeccamycin; 7-Azaindole; Antitumor compounds; Enzyme inhibitors.

* Corresponding author. Tel.: +33-4-7340-7124; fax: +33-4-7340-7717; e-mail: mprud@chimie.univ-bpclermont.fr






Figure 1.



Scheme 1.

For the synthesis of compound 1, we chose to use α -1-chloro-1-deoxy-2-*O*-tosyl-3,4,6-tri-*O*-benzyl glycopyra-


nose 7, prepared from triacetylated glycal 2 as shown in Scheme 2. Tribenzylated compound 3 was prepared




Scheme 2.

from commercial triacetylated glycal **2** according to a known method.¹¹ Epoxidation of **3** with dimethyldioxirane¹² provided the anhydro-sugar **4**. Reaction of **4** with glacial acetic acid led to compound **5** in 55% yield as a mixture of both α and β anomers in 3:10 ratio, respectively.^{13,14} Tosylation of **5** gave **6**¹⁵ in 84% yield as a mixture of the α and β anomers in 5:8 ratio, respectively, together with unreacted β anomer **5**. The anomeric mixture of **6** dissolved in diethylether was treated with HCl gas according to a method previously described in *altr*- and *allos*-pyranosyl series,¹⁶ to yield compound **7**¹⁷ in 66% yield as the α chloro anomer, the unreacted α **6** was recovered.

Coupling of the chloro-sugar **7** with the aglycone **8**¹⁸ was achieved in a heterogeneous medium. The reaction did not occur using KOH, Na₂SO₄ in acetonitrile as described by Ohkubo et al.^{19,20} for the synthesis of rebeccamycin analogues. The coupling reaction was carried out in acetonitrile, using KOH and tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) as a phase transfer catalyst, according to the method described by Seela and Bourgeois²¹ for the synthesis of nucleosides, to yield a mixture, which was partly purified by chromatography. The next step was the reaction with sodium azide in dimethylformamide leading to the bridged compound **9**²² in only 12% yield for the two steps, however in the



Scheme 3.



Scheme 4. Correlations observed in NMR experiments (chemical shifts in ppm).

coupling step, the unreacted aglycone **8** could be recovered (Scheme 3). The last step was the removal of the benzyl groups on the carbohydrate moiety using boron tribromide in dichloromethane.²³ Compound **1**²⁴ was obtained in 90% yield. The structure of compound **1** was assigned from ¹H COSY, HSQC, and HMBC NMR experiments (Scheme 4). These experiments allowed the assignment of the protons of the azaindole moiety. The correlations allowed the identification of the quaternary carbon at 152.8 ppm. A correlation was observed between this carbon and H₂₇. The regioselectivity of the coupling reaction with the sugar moiety is consistent with that already observed in the coupling using a heterogeneous medium in 7-azaindole series: the compound in which the sugar part is linked to the indole moiety was the major product of the reaction.¹⁰

In conclusion, we have successfully developed a method for the synthesis of 7-aza staurosporine analogues, which will be applied to prepare a new series by modifying the substituent at the imide nitrogen and/or by various substitutions on the aromatic rings and on the sugar moiety. The biological properties of these new azaindolocarbazoles will be evaluated.

References and notes

- Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchiya, H.; Takahashi, Y.; Masuma, R. *J. Antibiot.* **1977**, *30*, 275–282.
- Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. *Biochem. Biophys. Res. Commun.* **1986**, *135*, 397–402.
- Prudhomme, M. *Curr. Pharm. Des.* **1997**, *3*, 265–290.
- Knölker, H. J.; Reddy, K. R. *Chem. Rev.* **2002**, *102*, 4003–4427.
- Anizon, F.; Moreau, P.; Sancelme, M.; Voltaire, A.; Prudhomme, M.; Ollier, M.; Severe, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T.; Aubertin, A.-M. *Bioorg. Med. Chem.* **1998**, *6*, 1597–1604.
- Marminon, C.; Anizon, F.; Moreau, P.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Renard, P.; Prudhomme, M. *J. Med. Chem.* **2002**, *45*, 1330–1339.
- Bush, J. A.; Long, B. H.; Catino, J. J.; Bradner, W. T.; Tomita, K. *J. Antibiot.* **1987**, *40*, 668–678.
- Bailly, C.; Riou, J.-F.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M. *Biochemistry* **1997**, *36*, 3917–3929.
- Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Renard, P.; Prudhomme, M. *Bioorg. Med. Chem.* **2003**, *11*, 679–687.
- Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Joubert, A.; Bailly, C.; Renard, P.; Hickman, J.; Prudhomme, M. *J. Med. Chem.* **2003**, *46*, 609–622.
- Bovin, N. V.; Zurabyan, S. E.; Khorlin, A. Y. *Carbohydr. Res.* **1981**, *98*, 25–35.
- Murray, R. W.; Singh, M. *Org. Synth.* **1997**, *74*, 91–97.
- Timer, C. M.; van Straten, N. C. R.; van der Marel, G. A.; van Boom, J. H. *J. Carbohydr. Chem.* **1998**, *17*, 471–487.
- Takahashi, T.; Ebata, S.; Yamada, H. *Synlett* **1998**, 381–382.
- Spectral data of **6**: IR (film, NaCl) $\nu_{C=O}$ 1739, 1760 cm⁻¹. HRMS (FAB+) (M+Na)⁺ calcd for C₃₆H₃₈NaO₉S 669.2134, found 669.2147. ¹H NMR (400 MHz, CDCl₃) β major anomer, α minor anomer: 1.92 (3H ^{β} , s, CH₃), 2.11 (3H ^{α} , s, CH₃), 2.35 (3H ^{β} , s, CH₃ of OTs), 2.39 (3H ^{α} , s, CH₃ of OTs), 3.54–3.86 (m, 5H ^{β} +5H ^{α}), 4.43–4.82 (m, 7H ^{β} +7H ^{α}), 5.65 (1H ^{β} , d, J = 8.0 Hz, H₁ ^{β}), 6.18 (1H ^{α} , d, J = 3.5 Hz, H₁ ^{α}), 7.04–7.10 (m, 2H ^{β} +2H ^{α}), 7.14–7.36 (15H ^{β} +15H ^{α}), 7.73–7.79 (m, 2H ^{β} +2H ^{α}). ¹³C NMR (100 MHz, CDCl₃): 20.7, 20.9, 21.6, 21.8 (CH₃), 67.7, 67.8 (C₆), 73.6, 73.7, 75.2, 75.4, 75.5, 75.7 (CH₂ of OBn), 72.6, 75.8, 77.0, 77.4, 78.1, 79.5, 79.7, 82.4, 89.6, 91.5 (C₁, C₂, C₃, C₄, C₅), 127.6–128.6, 129.7, 130.0 (C tert arom), 133.2, 134.7, 137.6, 137.7, 137.8, 137.9, 144.7, 145.3 (C quat arom), 168.6, 169.3 (C=O).
- Du, Y.; Mao, F.; Kong, F. *Carbohydr. Res.* **1996**, *282*, 315–323.
- Spectral data of **7**: IR (film, NaCl) $\nu_{C=O}$ 1739 cm⁻¹. HRMS (FAB+) (M+Na)⁺ calcd for C₃₄H₃₅ClNaO₇S 645.1690, found 645.1699. ¹H NMR (400 MHz, CDCl₃): 2.39 (3H, s, CH₃), 3.66 (1H, dd, J_1 = 11.0 Hz, J_2 = 2.0 Hz), 3.76–3.83 (2H, m), 4.05 (1H, t, J = 9.5 Hz), 4.10 (1H, m), 4.48 (1H, d, J = 10.5 Hz), 4.48 (1H, d, J = 12.0 Hz), 4.60 (1H, d, J = 12.0 Hz), 4.60 (1H, dd, J_1 = 9.5 Hz, J_2 = 4.0 Hz), 4.69 (1H, d, J = 11.0 Hz), 4.74 (1H, d, J = 11.0 Hz), 4.75 (1H, d, J = 10.5 Hz), 6.21 (1H, d, J = 4.0 Hz, H₁), 7.08–7.11 (2H, m), 7.16–7.23 (4H, m), 7.25–7.37 (11H), 7.80 (2H, d, J = 8.5 Hz). ¹³C NMR (100 MHz, CDCl₃): 21.7 (CH₃ of OTs), 67.4 (C₆), 73.6, 75.4, 75.6 (CH₂ of OBn), 73.4, 76.6, 78.6, 79.1, 91.8 (C₁, C₂, C₃, C₄, C₅), 127.7, 127.8–128.1, 128.3, 128.4, 128.5 (C tert arom), 133.0, 137.5, 137.6, 137.7, 145.3 (C quat arom).
- Routier, S.; Ayerbe, N.; Mérour, J.-Y.; Coudert, G.; Bailly, C.; Pierré, A.; Pfeiffer, B.; Caignard, D.-H.; Renard, P. *Tetrahedron* **2002**, *58*, 6621–6630.
- Ohkubo, M.; Nishimura, T.; Jona, H.; Nakano, M.; Honma, T.; Morishima, H. *Tetrahedron* **1996**, *52*, 8099–8112.
- Ohkubo, M.; Kawamoto, H.; Ohno, T.; Nakano, M.; Morishima, H. *Tetrahedron* **1997**, *53*, 585–592.
- Seela, F.; Bourgeois, W. *Synthesis* **1990**, 945–950.
- Spectral data of **9**: Mp 67–69 °C. IR (KBr) $\nu_{C=O}$ 1700 cm⁻¹. HRMS (FAB+) (M+H)⁺ calcd for C₄₇H₃₉N₄O₆ 755.2870, found 755.2871.

¹H NMR signals of the sugar part were assigned from ¹H-¹H COSY.

¹H NMR (400 MHz, CDCl₃): 3.30 (3H, s, CH₃), 3.79 (1H, d, *J* = 11.0 Hz), 3.91 (1H, dd, *J*₁ = 10.5 Hz, *J*₂ = 5.5 Hz, H_{6'}), 3.96–4.03 (2H, m, H_{3'}, H_{6'}), 4.09 (1H, t, *J* = 9.5 Hz, H_{4'}), 4.42 (1H, m, H_{5'}), 4.44 (1H, d, *J* = 10.5 Hz), 4.65 (1H, d, *J* = 11.0 Hz), 4.67 (1H, d, *J* = 12.0 Hz), 4.75 (1H, d, *J* = 12.0 Hz), 4.92 (1H, d, *J* = 11.0 Hz), 5.53 (1H, m, H_{2'}), 6.15 (1H, d, *J* = 3.5 Hz, H_{1'}), 6.45 (2H, d, *J* = 7.0 Hz), 6.89 (2H, t, *J* = 7.5 Hz), 7.03 (1H, t, *J* = 7.5 Hz), 7.14–7.18 (2H, m), 7.24–7.28 (3H, m), 7.32–7.39 (2H, m), 7.40–7.49 (6H, m), 8.00 (1H, m), 8.52 (1H, d, *J* = 4.0 Hz), 8.82 (1H, m), 8.95 (1H, dd, *J*₁ = 8.0 Hz, *J*₂ = 1.0 Hz).

¹³C NMR (100 MHz, CDCl₃): 23.9 (NCH₃), 58.3, 74.5, 78.3, 80.4, 85.0 (C_{1'}, C_{2'}, C_{3'}, C_{4'}, C_{5'}), 68.9 (C_{6'}), 73.8, 75.1, 75.9 (CH₂ of OBn), 110.4, 113.3, 116.5, 117.7, 121.9, 125.3, 127.4, 130.2, 136.1, 137.6, 137.9, 143.3, 152.3 (C quat arom), 113.6, 117.3, 122.9, 125.6, 127.7–128.7, 134.1, 146.5 (C tert arom), 170.0, 170.1 (C=O).

23. Ward, D. E.; Gai, Y.; Kaller, B. F. *J. Org. Chem.* **1995**, *60*, 7830–7836.

24. Spectral data for **1**: Mp 245–250 °C (decomposition)
IR (KBr) $\nu_{\text{C=O}}$ 1700 cm⁻¹, ν_{OH} 3040–3680 cm⁻¹.
HRMS (FAB+) (M+H)⁺ calcd for C₂₆H₂₁N₄O₆ 485.1461, found 485.1465.

¹H NMR (400 MHz, DMSO-*d*₆): 3.19 (3H, s, NCH₃), 3.59–3.66 (2H, m), 3.79 (1H, m), 3.95–3.98 (1H, m), 4.06 (1H, m), 5.18–5.28 (3H, m, 2OH+H_{2'}), 5.40 (1H, d, *J* = 5.5 Hz, OH), 6.42 (1H, d, *J* = 4.0 Hz, H_{1'}), 7.49 (1H, dd, *J*₁ = 8.0 Hz, *J*₂ = 5.0 Hz), 7.51 (1H, t, *J* = 7.5 Hz), 7.64 (1H, dt, *J*₁ = 7.5 Hz, *J*₂ = 1.0 Hz), 8.24 (1H, d, *J* = 8.0 Hz), 8.63 (1H, dd, *J*₁ = 5.0 Hz, *J*₂ = 1.5 Hz), 8.72 (1H, d, *J* = 7.5 Hz), 8.89 (1H, dd, *J*₁ = 8.0 Hz, *J*₂ = 1.5 Hz).

¹³C NMR (100 MHz, DMSO-*d*₆): 23.6 (CH₃), 61.1 (C_{6'}), 59.2 (C_{2'}), 70.1, 73.6, 76.8 (C_{3'}, C_{4'}, C_{5'}), 84.6 (C_{1'}), 109.2, 114.6, 116.1, 120.1, 120.9, 124.4, 127.6, 130.2, 143.0, 152.8 (C quat arom), 114.1, 116.9, 122.1, 124.2, 127.7, 132.1, 146.9 (C tert arom), 169.5, 169.6 (C=O).